Dabigatran clinical trials antithrombotics

Pradax - Pradaxa

Acute coronary syndrome

All ACS (including AMI):  1 trials  - REDEEM

All type of patients:  1 trials  - REDEEM

Atrial fibrillation

All type of patients:  4 trials  - RE-LY (110mg) - RE-LY (150mg) - PETRO (150mg) - phase 2 dabigatran

Primary prevention of thromboembolic events:  4 trials  - RE-LY (110mg) - RE-LY (150mg) - PETRO (150mg) - phase 2 dabigatran

Secondary prevention of thromboembolic events:  2 trials  - RE-LY 110mg (2nd prevention subgroup) - RE-LY 150mg (2nd prevention subgroup)

Post acute coronary syndromes

1 trials  - REDEEM

Post myocardial infarction

1 trials  - REDEEM

Thrombosis prevention

elective major knee surgery :  4 trials  - RE-MOBILIZE (150mg) - RE-MOBILIZE (220mg) - RE-MODEL (150mg) - RE-MODEL (220mg)

All type of patients:  7 trials  - RE-MOBILIZE (150mg) - RE-MOBILIZE (220mg) - RE-MODEL (150mg) - RE-MODEL (220mg) - RE-NOVATE (150mg) - RE-NOVATE (220mg) - RE-NOVATE 2

Elective hip replacement:  3 trials  - RE-NOVATE (150mg) - RE-NOVATE (220mg) - RE-NOVATE 2

Elective major knee surgery :  4 trials  - RE-MOBILIZE (150mg) - RE-MOBILIZE (220mg) - RE-MODEL (150mg) - RE-MODEL (220mg)

Orthopaedic surgery:  7 trials  - RE-MOBILIZE (150mg) - RE-MOBILIZE (220mg) - RE-MODEL (150mg) - RE-MODEL (220mg) - RE-NOVATE (150mg) - RE-NOVATE (220mg) - RE-NOVATE 2

Orthopedic surgery:  7 trials  - RE-MOBILIZE (150mg) - RE-MOBILIZE (220mg) - RE-MODEL (150mg) - RE-MODEL (220mg) - RE-NOVATE (150mg) - RE-NOVATE (220mg) - RE-NOVATE 2

Venous thrombosis

secondary prevention of VTE :  2 trials  - RE-MEDY - RE-SONATE

All type of patients:  1 trials  - RE-COVER

All types of patients:  4 trials  - RE-COVER II - RE-MEDY - RE-SONATE - RE-COVER